These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36593601)

  • 1. Chalazion in a patient with multiple myeloma treated with bortezomib.
    Ghimire B; Hamajima Y; Carbajal-Carballo L; Anusim N
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
    Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
    Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres.
    McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A
    Bone Marrow Transplant; 2021 Mar; 56(3):738-740. PubMed ID: 33077903
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide, bortezomib and dexamethasone (CyBorD): a promising regimen for renal light chain deposit disease.
    Dutta A; Kesari K; Singh T
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31948981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data.
    Chan H; Chai K; Shih S; Lewsey R; Chen K; McDiarmid B; Jackson S; Simpson D
    Br J Haematol; 2019 Nov; 187(4):470-477. PubMed ID: 31298750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
    Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gray KS; Lutska Y; Bobba P; Qi K; Hoehn D; Qi M; Lin TS; Rifkin RM
    Leuk Lymphoma; 2022 Oct; 63(10):2383-2392. PubMed ID: 35730586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
    Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
    Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
    Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
    He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
    Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma].
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Rinsho Ketsueki; 2015 Aug; 56(8):1069-75. PubMed ID: 26345569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Bilateral Anterior Uveitis following Cyclophosphamide/ Bortezomid/ Dexamethasone (CyBorD) Protocol in a Newly Diagnosed Multiple Myeloma Patient with Concomitant Use of Zoledronic Acid.
    Karmiris E; Vasilopoulou MG; Chalkiadaki E
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1328-1331. PubMed ID: 32286130
    [No Abstract]   [Full Text] [Related]  

  • 13. A Case Report on Bortezomib-Induced Bilateral Chalazion.
    Paravathaneni M; Thota V; Mulla S; Thirumaran R; Thar YY
    Cureus; 2020 Aug; 12(8):e10062. PubMed ID: 32999785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
    Swan D; Henderson R; McEllistrim C; Naicker SD; Quinn J; Cahill MR; Mykytiv V; Lenihan E; Mulvaney E; Nolan M; Parker I; Natoni A; Lynch K; Ryan AE; Szegezdi E; Krawczyk J; Murphy P; O'Dwyer M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):847-852. PubMed ID: 35985959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iatrogenic Kaposi's sarcoma from induction therapy for myeloma: to transplant or not to transplant?
    Farrugia D; Sultana E; Babic D; Grech M
    BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37263679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
    Khan ML; Reeder CB; Kumar SK; Lacy MQ; Reece DE; Dispenzieri A; Gertz MA; Greipp P; Hayman S; Zeldenhurst S; Dingli D; Lust J; Russell S; Laumann KM; Mikhael JR; Leif Bergsagel P; Fonseca R; Vincent Rajkumar S; Keith Stewart A
    Br J Haematol; 2012 Feb; 156(3):326-33. PubMed ID: 22107129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
    Mouhieddine TH; Parekh S; Cho HJ; Richter J; DeCastro A; Shah J; Landesman Y; Chari A; Jagannath S; Madduri D
    Ann Hematol; 2021 Dec; 100(12):3057-3060. PubMed ID: 33009581
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.
    Krečak I; Ruščić I; Zlatović JJ; Šupe M; Krečak MV; Gverić-Krečak V
    Ann Hematol; 2021 Jun; 100(6):1623-1624. PubMed ID: 33404692
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.